Article

FGFR blockade inhibits targeted therapy-tolerant persister cells in basal FGFR1 and FGF2 high expressing cancers with driver oncogenes

2023-01-31

Abstract excerpt

Cancer cell resistance arises when tyrosine kinase inhibitor (TKI)-targeted therapies induce a drug-tolerant persister (DTP) state with growth via genetic aberrations, making DTP cells potential therapeutic targets. We screened an anti-cancer compound library and identified fibroblast growth factor receptor 1 (FGFR1) promoting alectinib-induced ALK fusion-positive DTP cell's survival. FGFR1 signaling promoted DTP...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 73080c52-fbec-58a3-949e-41725c85dacf
DOI: 10.21203/rs.3.rs-2357127/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

FGFR blockade inhibits targeted therapy-tolerant persister cells in basal FGFR1 and FGF2 high expressing cancers with driver oncogenesDOI 10.21203/rs.3.rs-2357127/v1Read

Targeting ErbB and tankyrase1/2 prevent the emergence of drug tolerant persister cells in ALK fusion positive lung cancerSemantic proximity Read

FGFR-TKI resistance in cancer: current status and perspectives.Semantic proximity Read

RAS-MAPK Reactivation Facilitates Acquired Resistance in FGFR1-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR-MEK Blockade.Semantic proximity Read

FGFR-driven lung cancer: Dissecting resistance and exploring therapeutic avenues.Semantic proximity Read

FGFR2 promotes resistance to ALK tyrosine kinase inhibitors and its inhibition acts synergistically with lorlatinib in the treatment of ALK-expressing neuroblastomaSemantic proximity Read

Mechanisms of rapid cancer cell reprogramming initiated by targeted receptor tyrosine kinase inhibitors and inherent therapeutic vulnerabilities.Semantic proximity Read

Targeting TROP2 in drug-tolerant persister cells delays EGFR tyrosine kinase inhibitor resistance in non-small-cell lung cancer.Semantic proximity Read

The landscape of therapeutic vulnerabilities in EGFR inhibitor osimertinib drug tolerant persister cellsSemantic proximity Read

Resiliency of lung cancers to EGFR inhibitor treatment unveiled, offering opportunities to divide and conquer EGFR inhibitor resistance.Semantic proximity Read

FGFR a promising druggable target in cancer: Molecular biology and new drugs.Semantic proximity Read

Future applications of FGF/FGFR inhibitors in cancer.Semantic proximity Read

GSTA1 Conferred Tolerance to Osimertinib and Provided Strategies to Overcome Drug-Tolerant Persister in EGFR-Mutant Lung Adenocarcinoma.Semantic proximity Read